期刊文献+

基于药代动力学特征定量评估金丝桃素肝肠首过效应

Quantitative evaluation the hepatic and intestinal first pass effect of hypericin based on pharmacokinetic characteristics
下载PDF
导出
摘要 目的:评价不同给药途径下金丝桃素(Hyp)大鼠体内药代动力学特征及定量评估其肝肠首过效应。方法:大鼠分别经十二指肠(id)和门静脉(ipv)置管建立给药模型,经id(100 mg·kg^(-1),200 mg·kg^(-1),400 mg·kg^(-1)),ipv(50 mg·kg^(-1),100 mg·kg^(-1),200 mg·kg^(-1)),外周静脉(iv,50 mg·kg^(-1),100 mg·kg^(-1),200 mg·kg^(-1))给予Hyp。高效液相色谱法测定血药浓度,采取浓度时间曲线下面积(AUC)计算Hyp生物利用度(BA)以及肝脏提取率(Eh)和肠道提取率(Ei)。结果:经id、ipv、iv给予不同剂量Hyp,其AUC值均随给药剂量升高而升高,剂量标准化后AUC值呈剂量非依赖性;AUC_(id)显著低于AUC_(ipv)和AUC_(iv)(P<0.05),而AUC_(ipv)和AUC_(iv)差异无统计学意义。各给药途径不同剂量间T_(1/2)和清除率差异无统计学意义。id给予100 mg·kg^(-1)和200 mg·kg^(-1)Hyp后,其BA分别为(4.53±0.6)%、(9.27±2)%,Eh分别为(17.89±4.82)%、(17.01±9.48)%,Ei为(94.49±1.73)%、(88.82±3.09)%。结论:经不同给药途径给予Hyp,其剂量标准化后的AUC值呈非剂量依赖性,增加药物剂量不能显著提高BA。Hyp经历显著首过效应,肠道是其首过效应主要发生部位。 Objective:To evaluate the pharmacokinetics characteristics of hypericin(Hyp)under different administration routes and quantitatively evaluate the hepatic and intestinal first-pass effect in rats.Methods:The rats were catheterized via duodenum(id)and portal vein(ipv).Different doses of Hyp were administered to rats via the id(100,200,400 mg·kg^(-1)),ipv(ipv,50,100,200 mg·kg^(-1))and iv port(50,100,200 mg·kg^(-1))respectively.The serum concentration of Hyp was determined by high performance liquid chromatography.The absolute bioavailability and hepatic and intestinal extraction ratio were calculated by the area under the plasma concentration-time curve(AUC).Results:The AUC values of Hyp with id,ipv and iv increased with the increase of drug dose.After dose normalization,AUC values did not show a dose-dependent manner.AUCid value was significantly lower than that of AUC_(ipv)and AUC_(iv)(P<0.05),while AUC_(ipv)and AUC_(iv)had no statistical significance.There was no significant difference in T_(1/2) and clearance rate among different dose routes.After 100 mg·kg^(-1)and 200 mg·kg^(-1)Hyp was administered via id port,the absolute bioavailability was(4.53±0.6)%and(9.27±2)%.The hepatic extraction ratios were(17.89±4.82)%,(17.01±9.48)%and the intestinal extraction ratios were(94.49±1.73)%,(88.82±3.09)%,respectively.Conclusion:The AUC value of Hyp was dose-independent after dose normalization via different administration routes,and the bioavailability of Hyp could not be significantly improved by increasing dose.Hyp underwent significant first pass effect,and intestinal tract was the main site of the first pass effect.
作者 苏远 张蒙蒙 姚婷婷 赵倩 王佳佳 章礼久 方海明 SU Yuan;ZHANG Meng-meng;YAO Ting-ting(The Second Hospital of Anhui Medical University,Hefei 230601,Anhui;不详)
出处 《安徽医专学报》 2022年第2期82-84,87,共4页 Journal of Anhui Medical College
关键词 金丝桃素 药物代谢动力学 生物利用度 首过效应 肠道首过效应 hypericin pharmacokinetics bioavailability first pass effect intestinal first pass effect
  • 相关文献

参考文献4

二级参考文献32

  • 1叶春苗,王淑琴,赵春燕.金丝桃素的研究进展[J].中兽医医药杂志,2007,26(1):28-29. 被引量:11
  • 2Kaminsky LS, Zhang QY. The small intestine as a xenobioticmetabolizing organ. Drug Metab Dispos 2003; 31:1520-5.
  • 3Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, et al. Impact of concentration and rate ofintraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin Pharmacol Ther 2004; 76: 230-8.
  • 4Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. AmJ Health Syst Pharm 1996; 53: 1401-15.
  • 5Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739- 54.
  • 6Kunta JR, Lee SH, Perry BA, Lee YH, Sinko PJ. Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. Drug Metab Dispos 2004; 32: 1293-8.
  • 7Hoffman D J, Seifert T, Borre A, Nellans HN. Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 1995; 12: 889-94.
  • 8Tam-Zaman N, Tam YK, Tawfik S, Wiltshire H. Factors responsible for the variability of saquinavir absorption: studies using an instrumented dog model. Pharm Res 2004; 21: 436-42.
  • 9Ward KW, Stelman G J, Morgan JA, Zeigler KS, Azzarano LM, Kehler JR, et al. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. Ⅱ. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey. Drug Metab Dispos 2004; 32: 172-7.
  • 10Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab 2004; 5: 109-24.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部